Crescent Capital BDC Inc. (CCAP)

CCAP experienced a stock price drop of over 10% due to uncertainty about its income potential and value proposition. CCAP's portfolio is 90% first-lien debt, with 85% in non-cyclical industries, ensur...

Crescent Capital BDC, Inc. offers a 10.6% dividend yield and trades at an 11% discount to book value, making it a compelling income investment. CCAP's portfolio is conservatively managed with 90% seni...

Investors need to pay close attention to Crescent Capital BDC (CCAP) stock based on the movements in the options market lately.

Market volatility underscores the need for income-producing assets; Crescent Capital BDC and Omega Healthcare Investors offer compelling value with strong fundamentals and attractive yields. Crescent ...

The essence of financial awareness is to realize that money can work for us through our investments. Understanding the value of money is the first step toward financial education, which leads to the s...

Crescent Capital BDC is downgraded due to a declining NII, and a less attractive discount to NAV. However, I don't see a reason for existing shareholders to sell. Despite recent weaknesses, CCAP maint...

A contrarian mindset can help dividend investors find bargains, with Crescent Capital BDC and Cenovus Energy offering high yields after recent price drops. Crescent Capital BDC carries a diversified d...

Crescent Capital BDC, Inc. (NASDAQ:CCAP ) Q4 2024 Earnings Conference Call February 20, 2025 ET Company Participants Dan McMahon - Head, IR Jason Breaux - CEO Henry Chung - President Gerhard Lombard -...

Crescent Capital BDC (CCAP) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.61 per share a year ago.

A rise in financing demand across sectors on the back of economic resilience and relatively low rates will support companies like Main Street Capital, Barings BDC and Crescent Capital amid weakening a...